Follow The Filings

AKTS Aktis Oncology Inc.

Health Care, filed as AKTIS ONCOLOGY INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Bought by 1 manager in 2026 Q2

  • 3 Owners
  • Max 2.5%
  • $21M
  • 1 new 1 small

In 2026 Q2 Polen Capital Management opened a position in Aktis Oncology.

Who owns this now

Largest portfolio weights among holders, up to 2.5% (David Witzke, Avidity Partners Management). Not free-float ownership.

  1. David Witzke Add 2.5%
  2. George Soros 0.04%
  3. Polen Capital Management New 0.02%

Who owns AKTS

Sorted by value, long equity only, as of 2026 Q2.

History
David Witzke, Avidity Partners Management 2.5%, was 2.0% Small add +3.3% 484,200 $16M History
George Soros, Soros Fund Management 0.04% Hold 100,000 $3.2M History
Polen Capital Management 0.02% New 0.02% 63,514 $2M History

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by AKTS's executives, directors and 10% owners in the last 12 months, from their Form 4s

All AKTS insider trades
  • $114M bought by 6 insiders
  • $3M sold by 3 insiders outside a trading plan
  • $259K sold by 1 insider under 10b5-1 plans
  1. Akos Czibere Chief Medical Officer
    Planned sale
    $259K 12,500 shares at $20.69 100% of stake
    Traded Sep 23 Filed Sep 24
  2. Ken Herrmann Director
    Sale
    $119K 4,856 shares at $24.56 100% of stake
    Traded Jul 20 Filed Jul 21
  3. Ken Herrmann Director
    Sale
    $77K 3,065 shares at $25.21 100% of stake
    Traded Jul 17 Filed Jul 20
  4. Shulamit Ron-Bigger COO
    Sale
    $1.4M 50,000 shares at $27.75 100% of stake
    Traded Jul 8 Filed Jul 10
  5. Akos Czibere Chief Medical Officer
    Sale
    $1.4M 50,000 shares at $27.77 100% of stake
    Traded Jul 8 Filed Jul 10
  6. Todd Foley Director
    Buy
    $4.2M 232,870 shares at $18.00 +5.8% to stake
    Traded Jan 12 Filed Jan 14
  7. Mpm Bioventures 2018, L.P. 10% owner, +7 joint filers
    Buy
    $20M 1,112,777 shares at $18.00 +12% to stake
    Traded Jan 12 Filed Jan 14
  8. Vida Ventures II, LLC 10% owner, +1 joint filer
    Buy
    $15M 835,000 shares at $18.00 New stake
    Traded Jan 12 Filed Jan 12
  9. EcoR1 Capital, LLC Director, +1 joint filer
    Buy
    $40M 2,222,222 shares at $18.00 New stake
    Traded Jan 12 Filed Jan 12

Also filed in the last 12 months, not counted as buying or selling: 17 conversions and 6 option exercises.

SEC filings

Recent issuer filings from EDGAR, 17 shown.

Filed Form Detail Links
8-K 2.02,9.01
10-Q
SCHEDULE 13G —
8-K 2.02,9.01
10-Q
8-K 5.02,7.01,9.01
10-K
8-K 2.02,9.01
SCHEDULE 13D —
SCHEDULE 13D —
SCHEDULE 13D —
SCHEDULE 13D —
8-K 5.03,9.01
424B4
S-1/A
S-1/A
S-1

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.

Further reading

As an Amazon Associate, FollowTheFilings earns from qualifying purchases.

More on the shelf